Quidelortho's Revenue in the fiscal year 2025 $ 2,730.20 millions
Quidelortho's Revenue in the fiscal year 2024 $ 2,782.90 millions
Quidelortho's Revenue in the fiscal year 2023 $ 2,997.80 millions
Quidelortho's Revenue in the fiscal year 2022 $ 3,266.00 millions
Quidelortho's Revenue in the fiscal year 2021 $ 1,698.55 millions
QDEL Revenue third quarter 2026 Y/Y Growth Comment
Quidelortho Corp reported fall in Revenue in the third quarter 2026 by -11.57% to $ 618.90 millions, from the same quarter in 2025. The decline in the third quarter 2026 Quidelortho Corp's Revenue compares unfavorably to the Company's average Revenue rise of 37.45%.
Looking into third quarter 2026 results within In Vitro & In Vivo Diagnostic Substances industry 5 other companies have achieved higher Revenue growth. While Quidelortho Corp' s Revenue decrease of -11.57% ranks overall at the positon no. 2450 in the third quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Quidelortho's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
188.62 %
11.58 %
-100 %
(Sep 30 2021)
QDEL's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Quidelortho Corp disclosed decrease in Revenue from the second quarter by -1.9% to $ 618.90 millions, from $ 630.90 millions achived in the previous reporting period.
Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue In Vitro & In Vivo Diagnostic Substances's company achievement, Most analysts pointed out.
Within In Vitro & In Vivo Diagnostic Substances industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Quidelortho's Revenue growth quarter on quarter, overall rank is 1436.
In the III. Quarter 2026 Quidelortho Corp disclosed decrease in Revenue from the second quarter by -1.9% to $ 618.90 millions, from $ 630.90 millions achived in the previous reporting period.
Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue In Vitro & In Vivo Diagnostic Substances's company achievement, Most analysts pointed out.
Within In Vitro & In Vivo Diagnostic Substances industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Quidelortho's Revenue growth quarter on quarter, overall rank is 1436.
Quidelortho's 12 Months Revenue Growth Year on Year
Quidelortho showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 29 2026. If the fiscal year would end in Jun 28 2026, Quidelortho's annual Revenue improvement would be -2.46% year on year to $2,674 millions.
In the Healthcare sector 389 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2705 to 2733.
Quidelortho showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 29 2026. If the fiscal year would end in Jun 28 2026, Quidelortho's annual Revenue fall would be -2.46% year on year to $2,674 millions.
In the Healthcare sector 389 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2705 to 2733.
About Quidelortho Revenue Growth Rates (QDEL), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
